Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study

PURPOSE: Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication–competent Δγ(1)34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Katherine E., Cassady, Kevin A., Roth, Justin C., Clements, Jennifer, Schieffer, Kathleen M., Leraas, Kristen, Miller, Anthony R., Prasad, Nripesh, Leavenworth, Jianmei W., Aban, Inmaculada B., Whitley, Richard J., Gillespie, G. Yancey, Mardis, Elaine R., Markert, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846434/
https://www.ncbi.nlm.nih.gov/pubmed/35105718
http://dx.doi.org/10.1158/1078-0432.CCR-21-2636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846434/
https://www.ncbi.nlm.nih.gov/pubmed/35105718
http://dx.doi.org/10.1158/1078-0432.CCR-21-2636

Ejemplares similares